Patents by Inventor Peter Dumovic

Peter Dumovic has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
    Publication number: 20080090878
    Abstract: The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
    Type: Application
    Filed: October 9, 2007
    Publication date: April 17, 2008
    Inventors: Stephan Billstein, Peter Dumovic, Nicola Franco, Mark Iwicki, Hans-Juergen Pfannkuche, Edward Wilusz
  • Pharmaceutical combinations and their use in treating gastrointestinal and abdominal viscera disorders
    Publication number: 20040092511
    Abstract: The present invention relates to a combination of a first agent including either a 5-HT4 receptor agonist or antagonist or a 5-HT3 receptor antagonist and a co-agent and pharmaceutical compositions and formulations containing the combination. The present invention also relates to a method of treating a gastrointestinal and abdominal viscera disorder by administering the pharmaceutical compositions to a patient. The pharmaceutical compositions may also be employed as laxatives, to prepare a patient for colonoscopy and to regulate and stabilize enterochromaffin cell secretory, pain and motility mechanisms, afferent fiber activity and GI and lower abdominal smooth muscle cells. The dosage is preferably oral and administration is preferably once or twice a day. The preferred first agent is tegaserod.
    Type: Application
    Filed: November 6, 2003
    Publication date: May 13, 2004
    Inventors: Stephan Anthony Billstein, Peter Dumovic, Nicola Franco, Mark Thomas Iwicki, Hans-Jurgen Pfannkuche, Edward Joseph Wilusz